THROMBOSES IN ONCOLOGY. PART 1
Atherothrombosis Journal
View Archive Info| Field | Value | |
| Title |
THROMBOSES IN ONCOLOGY. PART 1
ТРОМБОЗЫ В ОНКОЛОГИИ. ЧАСТЬ 1 |
|
| Creator |
Y. Fedotkina A.; Institute of Clinical Cardiology named after A.L. Myasnikov, MoH RF
E. Panchenko P.; Institute of Clinical Cardiology named after A.L. Myasnikov, MoH RF Ю. Федоткина А.; Институт клинической кардиологии им. А.Л. Мясникова Минздрава России Е. Панченко П.; Институт клинической кардиологии им. А.Л. Мясникова Минздрава России |
|
| Subject |
arterial thrombosis; oncological patients; prevention; treatment
артериальные тромбозы; онкологические больные; профилактика; лечение |
|
| Description |
Oncological disease increases the risk of developing arterial thrombosis mainly in the coronary and cerebrovascular beds. Among the pathogenetic mechanisms of this complication the authors consider the direct toxic effect on the endothelium produced by some groups of chemotherapeutic drugs, the procoagulant effect of the tumor, inhibition of endogenous fibrinolysis and increased platelet aggregation. Activation of the inflammation caused by increased synthesis of inflammatory mediators and adhesion molecules is also relevant, as well as vasospastic and direct damaging effects of radiation therapy on the endothelium. Patients with ACS against the background of the ongoing oncological process, on the one hand, are at a high risk for thrombotic complications, while, on the other hand, they have limitations for antiplatelet therapy due to thrombocytopenia. Therefore, the decision on the possibility, composition and duration of antiplatelet therapy in such patients should be taken by cardiologists jointly with oncologists and chemotherapists. The article has two parts. The first examines the specific hemo-stasis in cancer, some mechanisms of the pathogenesis of arterial and venous thrombosis, as well as treatment of cancer patients who developed arterial thrombosis. The second part provides a review of the literature on the prevention and treatment of venous thromboembolic complications associated with cancer.
Наличие онкологического заболевания повышает риск развития артериального тромбоза преимущественно в коронарном и цереброваскулярном русле. Среди патогенетических механизмов данного осложнения рассматривают прямой токсический эффект на эндотелий у некоторых групп химиопрепаратов, прокоагуляционный эффект опухоли, угнетение эндогенного фибринолиза и повышение агрегации тромбоцитов. Важным представляется и активизация воспаления за счет нарастания синтеза медиаторов воспаления и адгезивных молекул, а также вазоспастический и прямой повреждающий эффекты лучевой терапии на эндотелий. У больных с ОКС, возникшем на фоне активного онкопроцесса, с одной стороны, имеется высокий риск тромботических осложнений, а с другой — ограничения в антитромбоцитарной терапии из-за возникающей тромбоцитопении, поэтому в принятии решения о возможности, составе и длительности антитромбоцитарной терапии у подобных больных, наряду с кардиологами, должны участвовать онкологи и химиотерапевты. Статья представлена в двух частях. В первой рассматриваются особенности состояния гемостаза при онкологическом заболевании, некоторые механизмы патогенеза развития артериальных и венозных тромбозов, а также особенности развития и лечения онкологических пациентов с развитием артериальных тромбозов. Во второй части представлен обзор литературы по профилактике и лечению венозных тромбоэмболических осложнений, ассоциированных с онкологическим заболеванием. |
|
| Publisher |
«REMEDIUM GROUP» Ltd.
|
|
| Contributor |
—
— |
|
| Date |
2017-05-31
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — — |
|
| Format |
application/pdf
|
|
| Identifier |
http://www.aterotromboz.ru/jour/article/view/105
10.21518/2307-1109-2017-1-11-15 |
|
| Source |
Atherothrombosis Journal; № 1 (2017); 11-15
Атеротромбоз; № 1 (2017); 11-15 2307-1109 10.21518/2307-1109-2017-1 |
|
| Language |
rus
|
|
| Relation |
http://www.aterotromboz.ru/jour/article/view/105/149
Green KB, Silverstein RL. Hypercoagulobil-ity in cancer. Hemat. Onc. Clin. N. Am., 1996, 10: 499-530. Hillen HF. Thrombosis in cancer patients. ESMO Ann. Oncol., 2000, 11(Suppl. 3): 273-6. Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting, May 13-17, 2005: 748-777. Bromberg ME, Cappello M. Cancer and blood coagulation: molecular aspects. Cancer, 1999, 3: 132-8. Falanga A, Tickles FR. Pathophysiology of the thrombotic state in the cancer patient. Semin. Thromb. Haemostas., 1999, 25: 173-82. Сомонова О. Маджуга А., Елизарова А. Тромбозы и тромбоэмболии в онкологии. Современный взгляд на проблему. Злокачественные опухоли, 2014, 3(10). Bauer KA, Levine M. Evaluation and management of the cancer patient with thrombosis. Am. Soc. Clin. Oncol., 1999: 223-35. Loreto MF, Martinis DE, Corsi MP. Coagulation and cancer: implications for diagnosis and management. Pathol.Oncol. Res., 2000, 6(4): 302-12. Rickles F, Falanga A. A Molecular basis for the relationship between thrombosis and cancer. Thromb. Res., 2001, 102: 215-24. Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Hematologica, 1999, 84: 437-45. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am. Heart J, 1996, 132: 850-5. Agnelii G. Venous thromboembolism and cancer: two-way clinical association. Thromb. Haemost., 1997, 78(1): 117-20. Donati MB. Cancer and thrombosis. Haemostasis, 1994,24: 128-31. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb. Haemost., 1997, 78: 133-6. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncology, 2011, 29: 3466-3473. Zamorano JL, Lancellotti P, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxic-itr developed under the auspices of the ESC Committee for Practice Guidelines. EHJ. doi:10.1093/eurheat/ehw 211. Haugnes HS, Wethal T, AassN, et al. Cardiovascular risk factors and morbidity in long-term survivors of testricular cancer: a 20-year follow-up study. J Clin. Oncology, 2010, 28: 4649-4657. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as long-termcomplication of treatment for testicular cancer. J Clin Oncology, 2003, 21: 1513-1523. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomized, phase 3 trial. Lancet Oncol, 2013, 14: 933-942. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as long-termcomplication of treatment for testicular cancer. J Clin Oncology, 2003, 21: 1513-1523. McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, Fornander T, Gigante B, Jensen MB, Peto R, Rahimi K, TaylorCW, Ewertz M. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol, 2011, 100: 167-175. Virmani R, Farb A, Carter AJ, Jones RM. Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin Interv Cardiol, 1998, 3: 163-172. Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med, 1981, 70: 519-530. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol, 1996, 27: 766-773. McEniery PT, Dorosti K, Schiavone WA, Pedrick TJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol, 1987, 60: 1020-1024. King V, Constine LS, Clark D, Schwartz RG, Muhs AG, Henzler M, Hutson A, Rubin P. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys, 1996, 36: 881-889. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med, 2013, 368: 987-998. Storey MR, Munden R, Strom EA, McNeese MD, Buchholz TA. Coronary arterydosimetry in intact left breast irradiation. Cancer J, 2001, 7: 492-497. Windecker S, Kolh P, Alfonso F, et.al 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2014, 35: 2541-2619. Roffi M, Patrono C, Collet JP, Mueller C, Luis Zamorano J et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016, 37: 267-315. Steg PG, James SK, Atar D, Badano LP, et. al Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC),ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J, 2012, 33: 2569-2619. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation, 2016, 134: e123-e155. DOI:10.1161/CIR.0000000000000404. |
|
| Rights |
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
|